RxDoctor Payments DataLook up a doctor →

Bijan Ahrari, MD

Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1679726467

Payments from drug & device makers

$46,769in general payments, 2019–2025

Across 480 payments — averaging $97.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$22K
  • Sanofi-aventis U.S. LLC$10K
  • Johnson & Johnson$2K
  • Eli Lilly$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • plus $8K from 43 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Corcept Therapeutics44$21,746
Sanofi-aventis U.S. LLC32$10,199
Johnson & Johnson7$1,855
Eli Lilly22$1,694
Novo Nordisk68$1,514
Amgen(2 entities)37$1,387
Abbott40$950
AstraZeneca(2 entities)17$786
Dexcom, Inc.23$542
Xeris Pharmaceuticals, Inc.9$388
Chiesi USA, Inc.5$382
Recordati_rare_diseases_inc.9$378
Lilly USA, LLC19$374
Boehringer Ingelheim17$373
Neurocrine Biosciences, Inc.5$354
AbbVie11$325
Madrigal Pharmaceuticals4$300
Bayer5$284
Tandem Diabetes Care, Inc.2$238
Kyowa Kirin, Inc.4$205
Insulet Corporation5$205
Ascensia Diabetes Care US Inc.2$184
Merck6$173
Mannkind Corporation11$168
Amarin Pharma, Inc.18$154
Averitas Pharma Inc.3$140
BETA Bionics, Inc.3$133
Ascendis Pharma Endocrinology Inc1$125
Esperion Therapeutics, Inc.2$123
Ipsen Biopharmaceuticals, Inc1$117
IBSA Pharma Inc.6$115
Shire North American Group Inc5$95
Biomarin Pharmaceutical Inc.1$95
Pfizer5$90
Radius Health, Inc.4$76
Novartis3$65
Amryt Pharma Holdings Ltd3$52
Endo Pharmaceuticals Inc.3$50
Soleno Therapeutics, Inc.2$48
Lifescan, Inc.2$41
Antares Pharma, Inc.3$41
Boston Scientific3$40
Mylan Specialty L.p.1$34
Aytu Biopharma, Inc.2$30
Lexicon Pharmaceuticals, Inc.1$23
Eisai Inc.1$21
Medtronic1$21
Sequel Med Tech, LLC1$20
Almatica Pharma LLC1$15

How this compares

$46,769 in reported general payments places this provider in the 80th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Medicare billing

Part B allowed, 2024
$105,797
Medicare patients
397
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →